Dosing Information and Pathogen Coverage

IV or Oral ABSSSI Monotherapy Initiation

  • IV or oral monotherapy q12h
    • 300-mg IV infusion administered over 1 hour
    • 450-mg tablet
  • Option to start on IV and switch to oral

Straightforward Dosing for Patients with Comorbidities

  • No dosage adjustment due to:
    • Weight or body mass index (BMI)
    • Age
    • Diabetic status
    • Hepatic impairment
    • Mild to moderate renal impairment
      • Severe renal impairment requires dose adjustment in IV formulation
      • BAXDELA is not recommended in patients with end-stage renal disease (ESRD) due to insufficient information for dosing recommendations

Broad coverage: Gram +/- Pathogens, including MRSA

  • Efficacy against susceptible gram-negative, gram-positive, and mixed infections that include methicillin-resistant Staphylococcus aureus (MRSA)

Minimal Potential for Drug-Drug Interactions Demonstrated During Development

  • Do not administer any solution containing multivalent cations (eg, calcium and magnesium) through the same IV line
  • Oral BAXDELA should be taken 2 hours before or 6 hours after antacids or multivitamins containing iron or zinc
  • No drug-drug interactions due to CYP450

Next: Efficacy

BAXDELA is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.